Valuation : Sionna Therapeutics, Inc.

Market Cap 330M 284M 267M 244M 455M 31.29B 457M 3.16B 1.22B 15.99B 1.24B 1.21B 50.89B P/E 2026 *
-2.96x
P/E 2027 * -3.11x
Enterprise Value 184M 158M 149M 136M 253M 17.44B 255M 1.76B 682M 8.91B 691M 676M 28.36B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Sionna Therapeutics, Inc.

1 day+1.67%
1 week+13.00%
Current month+21.06%
1 month-85.70%
3 months-78.22%
6 months-79.68%
Current year-82.26%
1 week 6.62
Extreme 6.62
7.56
1 month 4.01
Extreme 4.01
7.56
Current year 4.01
Extreme 4.01
54.97
1 year 4.01
Extreme 4.01
54.97
3 years 4.01
Extreme 4.01
54.97
5 years 4.01
Extreme 4.01
54.97
10 years 4.01
Extreme 4.01
54.97
Manager TitleAgeSince
Corporate Officer/Principal - 01/08/2019
Corporate Officer/Principal - 01/08/2019
Chief Executive Officer 55 01/05/2021
Director TitleAgeSince
Director/Board Member 51 01/12/2019
Director/Board Member 44 01/12/2019
Director/Board Member 52 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26
OrbiMed Advisors Private Equity
SellCompany -85,918 0.1903%
07/07/26
OrbiMed Advisors Private Equity
SellCompany -85,918 0.1903%
06/07/26 Exercice

General Counsel

30,750 0.0681%
Change 5-day change 1-year change 3-year change Capi.($)
+1.67%+13.00%-66.23% - 330M
-0.95%-5.31%-2.81%+13.38% 48.01B
-1.29%-1.22%+404.92%+545.45% 44.44B
-3.20%+0.33%+38.11%+21.39% 42.67B
-1.89%-2.00%+1.45%+82.46% 39.96B
-1.72%-2.61%+13.09%+42.33% 32.75B
-0.17%+3.78% - - 17.74B
-0.07%+1.32%+20.08%+117.95% 16.49B
0.00%-2.17%+11.32%+31.41% 14.38B
-2.68%-0.56%+73.31%+40.56% 13.4B
Average -1.03%+0.87%+54.80%+111.87% 27.02B
Weighted average by Cap. -1.52%-1.03%+84.88%+132.55%

Financials

2026 *2027 *
Net sales - -
Net income -112M -96.6M -90.88M -82.94M -155M -10.65B -156M -1.08B -417M -5.44B -422M -413M -17.32B -116M -99.7M -93.8M -85.6M -160M -10.99B -161M -1.11B -430M -5.62B -435M -426M -17.88B
Net Debt -146M -126M -118M -108M -201M -13.85B -202M -1.4B -542M -7.08B -549M -537M -22.54B -183M -157M -148M -135M -252M -17.33B -253M -1.75B -678M -8.86B -686M -671M -28.19B
Logo Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Employees
59
Date Price Change Volume
08/09/26 $7.300 +1.67% 884,751
04/09/26 $7.180 +6.37% 926,065
03/09/26 $6.750 -7.66% 1,243,913
02/09/26 $7.310 +13.16% 1,590,547
01/09/26 $6.460 +7.13% 1,411,953
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
7.300USD
Average target price
15.17USD
Spread / Average Target
+107.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SION Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!